Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab. Cancer Biol Ther 2013 Oct 01;14(10):883-7
Date
08/07/2013Pubmed ID
23917487Pubmed Central ID
PMC3926884DOI
10.4161/cbt.25942Scopus ID
2-s2.0-84885216119 (requires institutional sign-in at Scopus site) 5 CitationsAbstract
RTOG 0839 is a Phase II study of pre-operative chemoradiotherapy with or without panitumumab in potentially operable locally advanced non-small cell lung cancer (NSCLC). The investigational agent, panitumumab, is an anti-epithelial growth factor receptor (EGFR) antibody that improves progression-free survival in chemorefractory metastatic colorectal cancer (mCRC). Recently, both KRAS mutational status (i.e., mutated or not) and subtype (i.e., activating or inactivating) have been shown to be predictive of response to anti-EGFR therapy in mCRC. However, in NSCLC, it is unknown if KRAS mutational status or subtype predict benefit to anti-EGFR therapies because of unique genetic and epigenetic factors unique to each cancer. We present a patient with stage III NSCLC containing a KRAS G12D activating mutation who had a partial pathologic response, with disappearance of a minor KRAS mutant clone. This case suggests possible eradication of the G12D KRAS lung cancer clones by concurrent chemoradiation with panitumumab.
Author List
Zaorsky NG, Sun Y, Wang Z, Palmer J, Fortina PM, Solomides C, Werner-Wasik M, Dicker AP, Axelrod R, Campling B, Evans N 3rd, Cowan S, Lu BMESH terms used to index this publication - Major topics in bold
Antibodies, MonoclonalAntineoplastic Combined Chemotherapy Protocols
Base Sequence
Carboplatin
Carcinoma, Non-Small-Cell Lung
Chemoradiotherapy
DNA Mutational Analysis
Female
Humans
Lung Neoplasms
Middle Aged
Mutation, Missense
Paclitaxel
Proto-Oncogene Proteins
Proto-Oncogene Proteins p21(ras)
Radiography
Treatment Outcome
ras Proteins
